ERG and CD31 expression in acute megakaryoblastic leukemia and myeloid sarcoma: A diagnostic pitfall.

Ann Diagn PatholAug 24, 2026 (epub)
Case ReportHematology

Ali Yılmaz Altay, Naciye Betül Barut, Simge Erdem et al.

✦ AI-curated · Sources linked

Case in brief

A case of acute megakaryoblastic leukemia (AMKL) presented as a soft tissue mass was misdiagnosed as composite hemangioendothelioma due to the co-expression of ERG and CD31. Further investigation revealed that while ERG expression was frequent and extensive in AMKL blasts, CD31 expression did not differ significantly from other myeloid neoplasms. Recognizing this co-expression is crucial for accurate diagnosis.

What made this case unusual

The co-expression of ERG and CD31 in AMKL mimicked vascular neoplasms, leading to diagnostic confusion with conditions like angiosarcoma.

Diagnostic / clinical pearl

Clinicians should be aware that ERG and CD31 co-expression in AMKL can lead to misdiagnosis as vascular tumors, particularly in extramedullary presentations.

Why it matters

This case highlights the importance of distinguishing between myeloid neoplasms and vascular tumors to prevent misinterpretation and ensure appropriate management.

Source

Published in Ann Diagn Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.